Sie suchten nach: levkopenije (Slowenisch - Englisch)

levkopenije, anemija
febrile neutropenia^◊, leucopenias◊

febrilna nevtropenija^◊, levkopenije◊
dehydration◊, hyponatraemia, hypocalcaemia

nevtropenija^, trombocitopenija^, anemija, levkopenije
thrombocytopenia^, anaemia, leucopenias

mediana časa do pojava levkopenije katerekoli stopnje je bila 85 dni.
median time to onset of any grade leukopenia was 85 days.

v kliničnih študijah so poročali o povezanosti levkopenije z beksarotensko terapijo.
leucopenia: leucopenia associated with bexarotene therapy has been reported in clinical studies.

pri uporabi paliperidona so poročali o primerih levkopenije, nevtropenije in agranulocitoze.
events of leucopenia, neutropenia, and agranulocytosis have been reported with paliperidone.

levkopenija: v kliničnih študijah so poročali o povezanosti levkopenije z beksarotensko terapijo.
leucopenia: leucopenia associated with bexarotene therapy has been reported in clinical studies.

poročali so o primerih agranulocitoze, trombocitopenije, levkopenije, aplastične anemije, pancitopenije in levkocitoze.
cases of agranulocytosis, thrombocytopenia, leukopenia, aplastic anaemia, pancytopenia and leucocytosis have been reported.

krvna izpostavljenost vinfluninu (auc) se dobro ujema z resnostjo levkopenije, nevtropenije in utrujenosti.
blood exposure to vinflunine (auc), significantly correlated with severity of leucopenia, neutropenia and fatigue.

prisotnost trombocitopenije lahko poveča tveganje za krvavitve, medtem ko lahko prisotnost nevtropenije ali levkopenije poveča tveganje za okužbo.
the presence of thrombocytopenia may increase the risk of bleeding, and the presence of neutropenia or leukopenia may increase the risk of infection.

spreminjanje odmerka zaradi levkopenije in trombocitopenije temelji na določitvi toksičnosti po nci ctcae in je enako kot pri zgoraj navedenih priporočilih za nevtropenijo.
dose modifications for leukopenia and thrombocytopenia are based on nci ctcae toxicity grading and are the same as recommended for neutropenia above.

priporočljivo je redno spremljanje števila trombocitov in belih krvnih celic, ker so med kliničnim ocenjevanjem opazili nekaj primerov reverzibilne trombocitopenije in levkopenije.
it is recommended that platelet and wbc counts are monitored regularly, as a few cases of reversible thrombocytopenia and leucopenia were observed during clinical evaluation.

pri bolnikih, ki so jemali zaviralce tnf, vključno z infliksimabom, so poročali o pojavu pancitopenije, levkopenije, nevtropenije in trombocitopenije.
there have been reports of pancytopenia, leucopenia, neutropenia, and thrombocytopenia in patients receiving tnf-blockers, including infliximab.

pri bolnikih, ki prejemajo zidovudin se lahko pričakuje pojav anemije, nevtropenije in levkopenije (navadno sekundarno po nevtropeniji).
anaemia, neutropenia and leucopenia (usually secondary to neutropenia) can be expected to occur in patients receiving zidovudine.

levkopenija je bila povezana z zmanjšanjem odmerka pri < 0,5 % bolnikov, zaradi levkopenije pa zdravljenja s krizotinibom ni trajno prekinil noben bolnik.
leukopenia was associated with a dose reduction for <0.5% of patients, and no patients permanently discontinued crizotinib treatment associated with leukopenia.

neželene hematološke reakcije: pri bolnikih, ki prejemajo zidovudin se lahko pričakuje pojav anemije, nevtropenije in levkopenije (navadno sekundarno po nevtropeniji).
haematological adverse reactions: anaemia, neutropenia and leucopenia (usually secondary to neutropenia) can be expected to occur in patients receiving zidovudine.

zdravljenje ukinite v primeru hude levkopenije (< 1.200/mm3), hude nevtropenije (< 750/mm3) ali hude trombocitopenije (< 70.000/mm3).
treatment should be discontinued in case of severe leukopaenia (< 1,200/mm3), severe neutropaenia (< 750/mm3) or severe thrombocytopaenia (< 70,000/mm3).